MCID: BNS007
MIFTS: 42

Bone Sarcoma

Categories: Bone diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Bone Sarcoma

MalaCards integrated aliases for Bone Sarcoma:

Name: Bone Sarcoma 58

Characteristics:

Orphanet epidemiological data:

58
bone sarcoma
Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe);

Classifications:

Orphanet: 58  
Rare bone diseases


External Ids:

UMLS via Orphanet 72 C0029463 C1704327
Orphanet 58 ORPHA223727

Summaries for Bone Sarcoma

MalaCards based summary : Bone Sarcoma is related to ewing sarcoma and neutropenia. An important gene associated with Bone Sarcoma is MTAP (Methylthioadenosine Phosphorylase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Miconazole and Dasatinib have been mentioned in the context of this disorder. Affiliated tissues include bone, kidney and lung, and related phenotypes are cardiovascular system and hematopoietic system

Related Diseases for Bone Sarcoma

Diseases related to Bone Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 408)
# Related Disease Score Top Affiliating Genes
1 ewing sarcoma 30.7 DES CSF3 CCNB3 BCOR
2 neutropenia 30.1 IL6 IL1RN CSF3 CSF1
3 sarcoma 30.0 TNFRSF1A SRC MTAP IL6 CXCL8
4 paracoccidioidomycosis 29.6 IL6 IL10 CTLA4
5 malignant mesenchymoma 29.6 MB DES
6 mesenchymoma 29.6 MB DES
7 acute cystitis 29.5 IL6 IL10 CXCL8
8 diarrhea 29.4 IL6 IL10 CXCL8 CSF3
9 spondylitis 29.3 IL6 IL1RN IL10
10 rhabdomyosarcoma 2 29.3 MB DES CCNB3 BCOR
11 osteomyelitis 29.2 IL6 IL1RN IL10 CXCL8 CSF3
12 spondyloarthropathy 1 29.2 TNFRSF1A IL1RN IL1R1
13 stomatitis 29.0 IL6 IL1RN IL10 CXCL8 CSF3
14 exanthem 28.9 IL6 IL1RN IL10 CXCL8 CTLA4 CSF3
15 synovitis 28.8 TNFRSF1A IL6 IL1RN CXCL8
16 toxic shock syndrome 28.6 IL6 IL1RN IL1R1 IL10 CXCL8
17 bone inflammation disease 28.2 TNFRSF1A IL6 IL1RN IL10 CXCL8 CTLA4
18 severe combined immunodeficiency 28.2 IL6 IL1RN IL1R1 IL18R1 IL10 CSF3
19 thrombocytopenia 28.0 SRC IL6 IL1RN IL10 CXCL8 CTLA4
20 myeloma, multiple 27.3 TNFRSF1A SRC IL6 IL10 CXCL8 CTLA4
21 systemic lupus erythematosus 27.2 TNFRSF1A IL6 IL1RN IL1R1 IL10 CXCL8
22 osteogenic sarcoma 11.7
23 diaphyseal medullary stenosis with malignant fibrous histiocytoma 11.3
24 li-fraumeni syndrome 11.1
25 li-fraumeni syndrome 2 11.1
26 spindle cell sarcoma 10.8
27 soft tissue sarcoma 10.6
28 chondrosarcoma 10.6
29 leukoregulin 10.5 CXCL8 CSF1
30 small cell sarcoma 10.5 CCNB3 BCOR
31 engraftment syndrome 10.4 CXCL8 CSF3
32 spotted fever rickettsiosis 10.4 IL10 CTLA4
33 kidney sarcoma 10.4 CCNB3 BCOR
34 dermatitis, atopic, 8 10.4 IL10 CXCL8
35 doxorubicin induced cardiomyopathy 10.4 DES CSF3
36 neurosyphilis 10.4 IL10 CXCL8
37 ossifying fibromyxoid tumor 10.3 DES CCNB3 BCOR
38 cyclic neutropenia 10.3 CXCL8 CSF3 CSF1
39 leiomyosarcoma 10.3
40 pouchitis 10.3 IL1RN CXCL8
41 undifferentiated pleomorphic sarcoma 10.3
42 histiocytoma 10.3
43 idiopathic anterior uveitis 10.3 IL6 CXCL8
44 streptococcal toxic-shock syndrome 10.3 IL6 CXCL8
45 fibrous histiocytoma 10.3
46 paraneoplastic syndromes 10.3 IL6 CSF3
47 scabies 10.2 IL10 CXCL8 CSF3
48 malignant fibroxanthoma 10.2
49 progressive muscular dystrophy 10.2 MTAP MB
50 small cell osteogenic sarcoma 10.2 CCNB3 BCOR

Graphical network of the top 20 diseases related to Bone Sarcoma:



Diseases related to Bone Sarcoma

Symptoms & Phenotypes for Bone Sarcoma

MGI Mouse Phenotypes related to Bone Sarcoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.23 BCOR CSF1 CTLA4 DES IL10 IL18R1
2 hematopoietic system MP:0005397 10.18 BCOR CSF1 CSF3 CTLA4 IL10 IL18R1
3 cellular MP:0005384 10.17 BCOR CCNB3 CSF1 DES IL10 IL1R1
4 immune system MP:0005387 10.15 BCOR CSF1 CSF3 CTLA4 IL10 IL18R1
5 integument MP:0010771 9.97 CSF1 CSF3 CTLA4 IL10 IL1R1 IL1RN
6 mortality/aging MP:0010768 9.93 BCOR CSF1 CTLA4 DES IL10 IL1R1
7 liver/biliary system MP:0005370 9.8 CSF1 CTLA4 IL10 IL1R1 IL6 MTAP
8 muscle MP:0005369 9.5 CSF1 DES IL10 IL1R1 IL6 MB
9 respiratory system MP:0005388 9.28 CSF1 CTLA4 IL10 IL1R1 IL6 MB

Drugs & Therapeutics for Bone Sarcoma

Drugs for Bone Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 98)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
2
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
3
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
4
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
5
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
6
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
7
Vidarabine Approved, Investigational Phase 2 24356-66-9 32326 21704
8
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
9
Pembrolizumab Approved Phase 2 1374853-91-4
10
nivolumab Approved Phase 1, Phase 2 946414-94-4
11
Sunitinib Approved, Investigational Phase 1, Phase 2 341031-54-7, 557795-19-4 5329102
12
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
13
Ifosfamide Approved Phase 2 3778-73-2 3690
14
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
15
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
16
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
17
leucovorin Approved Phase 2 58-05-9 6006 143
18
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
19
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
20
Lenograstim Approved, Investigational Phase 2 135968-09-1
21
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
22
Vitamin C Approved, Nutraceutical Phase 2 50-81-7 5785 54670067
23
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
24 Exatecan Investigational Phase 2 171335-80-1
25
Camptothecin Experimental Phase 2 7689-03-4
26
Emodepside Investigational, Vet_approved Phase 2 155030-63-0
27 Interferon-alpha Phase 2
28 Interferon alpha-2 Phase 2
29 interferons Phase 2
30 Anti-Infective Agents Phase 2
31 Antihypertensive Agents Phase 2
32 Veratrum Alkaloids Phase 2
33 Imatinib Mesylate Phase 2 220127-57-1 123596
34 Antibodies, Monoclonal Phase 2
35 Antifungal Agents Phase 2
36 Cyclosporins Phase 2
37 Calcineurin Inhibitors Phase 2
38 Interleukin-2 Phase 2
39 Anti-Retroviral Agents Phase 2
40 Analgesics, Non-Narcotic Phase 2
41 Anti-HIV Agents Phase 2
42 Analgesics Phase 2
43 Vidarabine Phosphate Phase 2
44 Angiogenesis Inhibitors Phase 1, Phase 2
45 Antineoplastic Agents, Immunological Phase 2
46 Immunoglobulins Phase 2
47 Antibodies Phase 2
48 Pharmaceutical Solutions Phase 1, Phase 2
49 Antiviral Agents Phase 2
50 Anti-Bacterial Agents Phase 2

Interventional clinical trials:

(show all 43)
# Name Status NCT ID Phase Drugs
1 Phase II Study of Low-Dose Interferon Alfa 2B (Schering Plough) Plus Thalidomide (Celgene) for Patients With Resected High-Risk Soft Tissue Sarcoma Unknown status NCT00026416 Phase 2 thalidomide
2 PhaseⅡ Study of Weekly Docetaxel and Fixed-Dose Rate Gemcitabine in Patient With Previously Treated Advanced Soft Tissue and Bone Sarcoma Prospective, Open Label, Multi-Institutional Unknown status NCT00807261 Phase 2 Gemcitabine and Docetaxel
3 A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma Completed NCT01310816 Phase 2 IPI-926;Placebo Arm
4 Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00031915 Phase 2 imatinib mesylate
5 A Phase 2 Study of Temsirolimus (CCI-779, NSC 683864) and IGF-1 Receptor Antibody Cixutumumab (IMC-A12, NSC 742460) in Patients With Metastatic Sarcomas Completed NCT01016015 Phase 2 Temsirolimus
6 Exatecan As Second-Line Treatment In Advanced Adult Soft Tissue Sarcoma: A Phase II - Study Of The EORTC Soft Tissue And Bone Sarcoma Group Completed NCT00041236 Phase 2 exatecan mesylate
7 A Phase II Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
8 Phase II Trial of Linsitinib (Anti-IGF-1R/IR) in Patients With Relapsed and/or Refractory Ewing Sarcoma Completed NCT02546544 Phase 2 Linsitinib
9 Exploratory Study of Non-Myeloablative Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusions for Metastatic Neoplasms Refractory to Standard Therapy Completed NCT00001880 Phase 2 methotrexate;cyclosporin
10 Determination of Tumor Response Rate by RECIST and FDG-PET Criteria to Dacarbazine in Metastatic Soft Tissue and Bone Sarcoma Completed NCT00802880 Phase 2 Dacarbazine
11 A Phase II Study to Evaluate the Pharmacokinetics, Safety, and Obtain a Preliminary Efficacy Assessment of Palifermin in Patients With Sarcoma Receiving Multicycle Chemotherapy With Doxorubicin and Ifosfamide Completed NCT00267046 Phase 2 Palifermin;Placebo;Adriamycin (Doxorubicin);Ifosfamide;Vincristine;Cisplatin
12 Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration Recruiting NCT04040205 Phase 2 Abemaciclib
13 Clinical Study to Assess Efficacy and Safety of LN-145 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types Recruiting NCT03449108 Phase 2 Cyclophosphamide;Fludarabine;Fludarabine Phosphate
14 SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas Active, not recruiting NCT02301039 Phase 2 Pembrolizumab
15 Phase I-II Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas Active, not recruiting NCT03277924 Phase 1, Phase 2 Sunitinib 37.5 MG [Sutent];Nivolumab 10 MG/ML [Opdivo]
16 Phase I/ II Study of Pulmonary Suffusion to Control Minimal Residual Disease in Resectable Sarcoma Pulmonary Metastases Not yet recruiting NCT03965234 Phase 1, Phase 2 Cisplatin
17 A Phase II Trial of Gemcitabine Plus High-Dose Ascorbate in Locally Advanced Unresectable or Metastatic Soft Tissue and Bone Sarcomas in Adults Suspended NCT03468075 Phase 2 Ascorbate;Gemcitabine
18 A Phase II Study of Sorafenib and Ifosfamide as a Treatment for Patients With Sarcoma Terminated NCT00880542 Phase 2 sorafenib;Ifosfamide
19 Phase II Trial of Neoadjuvant Dose-Dense Doxorubicin, Ifosfamide, and Irinotecan (CPT-11) for Advanced Soft Tissue and Recurrent Bone Sarcomas Terminated NCT00544778 Phase 2 dexrazoxane hydrochloride;doxorubicin hydrochloride;ifosfamide;irinotecan hydrochloride
20 A Randomised, Cross-over Phase II Study to Investigate the Efficacy and Safety of Glucarpidase for Routine Use After High Dose Methotrexate in Patients With Bone Sarcoma Terminated NCT02022358 Phase 2 Glucarpidase;Methotrexate;Folinic Acid
21 An Open-Label Phase IB Trial To Evaluate the Effects of Food and Formulation on Pharmacokinetics of the Oral Selective Inhibitor of Nuclear Export/SINE Compound KPT-330 in Patients With Soft-Tissue or Bone Sarcoma Completed NCT01896505 Phase 1 KCP-330
22 To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in Bone and Soft Tissue Sarcoma Recruiting NCT03462316 Phase 1
23 In Vivo Lung Perfusion (IVLP) as an Adjuvant Treatment for Patients Undergoing Surgical Resection of Pulmonary Metastases of Bone and Soft Tissues Sarcomas Recruiting NCT02811523 Phase 1 Doxorubicin
24 A Phase I/II Open-label Study of Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia (CIT) in Subjects With Advanced Soft Tissue and Bone Sarcomas Receiving Gemcitabine and Docetaxel Chemotherapy Terminated NCT01491594 Phase 1 Eltrombopag
25 A Multi-center Phase I Trial of Temsirolimus in Combination With Valproic Acid in Children and Adolescents With Multiply Relapsed Pediatric Solid Tumors Terminated NCT01204450 Phase 1 Temsirolimus;Valproic Acid
26 Osteosarcoma and Ewing Sarcoma Treatment Response Assessment With Functional MRI Imaging in Children and Young Adults Unknown status NCT01780779
27 Neutrophil Extracellular Traps (NETs) Formation Following Chemotherapy for Pediatric Hematological and Solid Tumors, and Its Relation to Other Neutrophil Functions and the Role of NETs in Antitumor Activity Unknown status NCT01533779
28 Quantifying and Measuring the Economic Impact of Nursing Activities During the Hospital Stay of High Complexity Oncologic Care Patients Unknown status NCT02845583
29 Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment Completed NCT00824083
30 A European Treatment Protocol for Bone-sarcoma in Patients Older Than 40 Years Completed NCT02986503 Doxorubicin+cisplatin+ifosfamide;Doxorubicin+cisplatin+ifosfamide+methotrexate
31 Long Term Clinical and Functional Outcome in Patients Operated on Van Ness-Borggreve Rotationplasty for Lower Limnb Bone Tumor Completed NCT03385694
32 Dynamic Contrast Enhanced MRI(DCE-MRI)of Bone Tumors Completed NCT00598741
33 Clinical Evaluation for Sarcoma Originated From Bone Recruiting NCT03358992
34 Pre-Surgical Supervised Exercise for Bone Cancer Patients Recruiting NCT02893397
35 Transcultural Validation of MSTS and TESS Questionnaire Recruiting NCT03765970
36 ICONIC: Improving Outcomes Through Collaboration in OsteosarComa Recruiting NCT04132895
37 Incorporating the Patient Voice in Sarcoma Research: How Can we Assess Health-related Quality of Life in This Heterogeneous Group of Patients? Recruiting NCT04071704
38 Assessment of Healing and Function After Surgical Reconstruction for Osseous Sarcomas Recruiting NCT03442465
39 Observational Study, for Quality Assessment, of Sarcoma as a Model to Improve Diagnosis and Clinical Care of Rare Tumors Through a European and Latin American Multidisciplinary NETWORK Recruiting NCT04181970
40 Etiosarc: Study of the Environmental Aetiology (Environment, Occupations and Lifestyle) of Sarcomas (Soft Tissue, Visceral and Bone) From a Multicenter French Population-based Case-control Study Among Adults. Recruiting NCT03670927
41 DVT Prophylaxis in Orthopaedic Oncology Patients - A Safety Study Active, not recruiting NCT00525057 Dalteparin
42 Prospective Evaluation of Abscopal Radiation Effects on Regional and Distant Bone Enrolling by invitation NCT03134742
43 A Randomized, Placebo-controlled, Double-blinded, Multicentre Study Evaluating the Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas Not yet recruiting NCT04055220 Treatment by Regorafenib;Treatment by Placebo

Search NIH Clinical Center for Bone Sarcoma

Genetic Tests for Bone Sarcoma

Anatomical Context for Bone Sarcoma

MalaCards organs/tissues related to Bone Sarcoma:

40
Bone, Kidney, Lung, T Cells, Eye, Breast, Brain

Publications for Bone Sarcoma

Articles related to Bone Sarcoma:

(show top 50) (show all 802)
# Title Authors PMID Year
1
The miR-143/145 Cluster, a Novel Diagnostic Biomarker in Chondrosarcoma, Acts as a Tumor Suppressor and Directly Inhibits Fascin-1. 61
32027760 2020
2
Sacral chordoma: do the width of surgical margin and the use of photon/proton radiotherapy affect local disease control? 61
31863159 2020
3
Omic approaches to pediatric bone sarcomas. 61
31736201 2020
4
Experiences of return to work after treatment for extremital soft tissue or bone sarcoma: Between distraction and leaving the disease behind. 61
32017298 2020
5
Use of a simple form to facilitate communication on long-term consequences of treatment in sarcoma survivors. 61
31969978 2020
6
The long-term results of extendable endoprostheses of the humerus in children after the resection of a bone sarcoma. 61
31888359 2020
7
Long-term outcomes of limb salvage treatment with custom-made extendible endoprosthesis for bone sarcoma around the knee in children. 61
31948458 2020
8
Application of Low Doses of Ionizing Radiation in Medical Therapies. 61
31933547 2020
9
[Treatment concepts for complications after resection and defect reconstruction of pelvic tumours]. 61
31996946 2020
10
Oncological and endoprosthetic outcomes of bone sarcoma patients: a nationwide cohort study. 61
31324968 2020
11
Upregulation of miRNA-154-5p prevents the tumorigenesis of osteosarcoma. 61
32000044 2020
12
The sensitivity, specificity, and diagnostic accuracy of whole-bone MRI for identifying skip metastases in appendicular osteosarcoma and Ewing sarcoma. 61
31900513 2020
13
Bone sarcomas in the immunotherapy era. 61
31975481 2020
14
The incidence of skip metastases on whole bone MRI in high-grade bone sarcomas. 61
31919587 2020
15
Primary bone sarcoma with BCOR internal tandem duplication. 61
31900635 2020
16
The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. 61
32004793 2020
17
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. 61
31704134 2019
18
Selective Agonists of Nuclear Retinoic Acid Receptor Gamma Inhibit Growth of HCS-2/8 Chondrosarcoma Cells. 61
31808569 2019
19
Bone and Soft-Tissue Sarcoma Risk in Long-Term Survivors of Hereditary Retinoblastoma Treated With Radiation. 61
31622129 2019
20
Incidence, mortality, and survival trends of soft tissue and bone sarcoma in Switzerland between 1996 and 2015. 61
31520938 2019
21
Pediatric extremity bone sarcoma reconstruction with the vascularized fibula flap: Observational study assessing long-term functional outcomes, complications, and survival. 61
31563475 2019
22
Diagnostic accuracy of primary bone and soft tissue sarcomas by 18-FDG PET: Systematic review and meta-analysis. 61
31887730 2019
23
What is the Likelihood That Tumor Endoprostheses Will Experience a Second Complication After First Revision in Patients With Primary Malignant Bone Tumors And What Are Potential Risk Factors? 61
31764339 2019
24
The association between socioeconomic position and tumour size, grade, stage, and mortality in Danish sarcoma patients - A national, observational study from 2000 to 2013. 61
31702424 2019
25
Antiproliferative effect of the histone demethylase inhibitor GSK-J4 in chondrosarcomas. 61
31241814 2019
26
The adrenergic receptor antagonists propranolol and carvedilol decrease bone sarcoma cell viability and sustained carvedilol reduces clonogenic survival and increases radiosensitivity in canine osteosarcoma cells. 61
31778284 2019
27
Construction of Anti-hPD-L1 HCAb Nb6 and in Situ124I Labeling for Noninvasive Detection of PD-L1 Expression in Human Bone Sarcoma. 61
31535847 2019
28
Radiotherapy for the Palliation of Advanced Sarcomas-The Effectiveness of Radiotherapy in Providing Symptomatic Improvement for Advanced Sarcomas in a Single Centre Cohort. 61
31635409 2019
29
Factors associated with functional outcome in patients having limb salvage surgery for primary malignant bone sarcoma using TESS. 61
31528081 2019
30
Ion channels in sarcoma: pathophysiology and treatment options. 61
31377822 2019
31
[The importance of radiology in bone sarcoma diagnostics : Initial and advanced diagnostics]. 61
31392388 2019
32
Identifying bone sarcoma survivors facing psychosocial challenges. A study of trajectories following treatment. 61
31184795 2019
33
Stanmore noninvasive extendible endoprosthesis in the treatment of bone sarcoma in the preadolescent. 61
31093984 2019
34
Bone Sarcoma With EWSR1-NFATC2 Fusion: Sarcoma With Varied Morphology and Amplification of Fusion Gene Distinct From Ewing Sarcoma. 61
30714449 2019
35
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations. 61
31434953 2019
36
The m6A methyltransferase METTL3 promotes osteosarcoma progression by regulating the m6A level of LEF1. 61
31253399 2019
37
What is the Likelihood That Tumor Endoprostheses Will Experience a Second Complication After First Revision in Patients With Primary Malignant Bone Tumors And What Are Potential Risk Factors? 61
31490349 2019
38
Can Navigation Improve the Ability to Achieve Tumor-free Margins in Pelvic and Sacral Primary Bone Sarcoma Resections? A Historically Controlled Study. 61
31107331 2019
39
CORR® Tumor Board: Can Navigation Improve the Ability to Achieve Tumor-free Margins in Pelvic and Sacral Primary Bone Sarcoma Resections? A Historically Controlled Study. 61
31169622 2019
40
CORR Insights®: Can Navigation Improve the Ability to Achieve Tumor-free Margins in Pelvic and Sacral Primary Bone Sarcoma Resections? A Historically Controlled Study. 61
31135541 2019
41
SFCE METRO-01 four-drug metronomic regimen phase II trial for pediatric extracranial tumor. 61
30920117 2019
42
Management of Sarcoma in Adolescents and Young Adults: An Australian Population-Based Study. 61
30822262 2019
43
Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice. 61
30956944 2019
44
Assessment of resection margins in bone sarcoma treated by neoadjuvant chemotherapy: Literature review and guidelines of the bone group (GROUPOS) of the French sarcoma group and bone tumor study group (GSF-GETO/RESOS). 61
30962172 2019
45
Bone sarcoma incidence in the Netherlands. 61
30903831 2019
46
Resection margins obtained with patient-specific instruments for resecting primary pelvic bone sarcomas: A case-control study. 61
30982774 2019
47
Deep integrative analysis of microRNA-mRNA regulatory networks for biomarker and target discovery in chondrosarcoma. 61
30520120 2019
48
Current review of surgical management options for extremity bone sarcomas. 61
31191985 2019
49
Effective nutritional status screening in orthopaedic oncology patients and post-operative complications. 61
31084248 2019
50
Decision-making in Orthopaedic Oncology: Does Cognitive Bias Affect a Virtual Patient's Choice Between Limb Salvage and Amputation? 61
31173578 2019

Variations for Bone Sarcoma

Expression for Bone Sarcoma

Search GEO for disease gene expression data for Bone Sarcoma.

Pathways for Bone Sarcoma

Pathways related to Bone Sarcoma according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.94 TNFRSF1A SRC IL6 IL1RN IL1R1 IL18R1
2
Show member pathways
13.75 TNFRSF1A SRC IL6 IL1R1 IL18R1 IL10
3
Show member pathways
13.5 TNFRSF1A SRC IL6 IL1RN IL1R1 IL18R1
4
Show member pathways
13.23 TNFRSF1A SRC IL6 IL1R1 IL18R1 IL10
5
Show member pathways
13.09 TNFRSF1A SRC IL6 IL1R1 IL18R1 IL10
6
Show member pathways
12.96 TNFRSF1A SRC IL6 IL1RN IL1R1 IL18R1
7
Show member pathways
12.86 TNFRSF1A SRC IL6 IL1R1 CXCL8 CCNB3
8 12.32 TNFRSF1A SRC IL1R1 CXCL8
9 12.23 TNFRSF1A IL6 IL1R1 CXCL8
10 12.17 TNFRSF1A SRC IL6 IL10
11
Show member pathways
12.13 TNFRSF1A IL6 IL18R1 IL10 CXCL8 CSF1
12 12.1 IL6 IL1RN IL10 CXCL8
13 12.02 TNFRSF1A SRC IL1R1 GSTA1
14
Show member pathways
11.98 IL6 IL1R1 IL18R1 IL10
15 11.94 SRC IL6 IL10 CXCL8
16 11.9 IL6 IL10 CSF3 CSF1
17 11.87 SRC IL6 CXCL8
18 11.87 TNFRSF1A IL6 IL18R1 CSF1
19 11.85 TNFRSF1A IL1R1 CXCL8
20 11.82 IL6 IL1R1 IL10 CXCL8
21
Show member pathways
11.81 IL6 CXCL8 CSF3
22 11.79 IL6 IL1R1 CSF3 CSF1
23 11.75 IL6 CXCL8 CTLA4 CSF1
24 11.72 IL6 IL10 CXCL8
25 11.7 IL6 IL10 CSF1
26
Show member pathways
11.68 SRC IL6 IL1RN IL1R1 IL18R1 CXCL8
27 11.67 IL6 IL1RN IL10
28 11.63 SRC IL6 CXCL8
29
Show member pathways
11.61 TNFRSF1A IL6 CXCL8
30 11.61 IL6 CXCL8 CSF3
31 11.46 IL6 CSF3 CSF1
32 11.45 SRC IL6 CXCL8
33 11.4 IL6 IL10 CXCL8 CSF3
34 11.02 IL6 IL10 CSF3 CSF1
35 10.93 IL6 IL10 DES CXCL8 CSF3 CSF1
36 10.92 TNFRSF1A IL6 IL1RN IL1R1 IL10 CXCL8

GO Terms for Bone Sarcoma

Biological processes related to Bone Sarcoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.02 TNFRSF1A SRC IL6 IL1RN IL1R1 IL18R1
2 immune response GO:0006955 9.76 IL6 IL1RN IL1R1 IL18R1 IL10 CXCL8
3 cellular response to lipopolysaccharide GO:0071222 9.73 SRC IL6 IL1RN IL10 CXCL8 CSF3
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.67 SRC IL6 CSF3
5 response to glucocorticoid GO:0051384 9.61 IL6 IL1RN IL10
6 inflammatory response GO:0006954 9.56 TNFRSF1A IL6 IL1RN IL1R1 IL18R1 IL10
7 branching involved in mammary gland duct morphogenesis GO:0060444 9.51 SRC CSF1
8 response to molecule of bacterial origin GO:0002237 9.48 IL10 CXCL8
9 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.46 IL1RN IL10
10 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.4 IL6 IL1RN
11 positive regulation of T-helper 1 cell cytokine production GO:2000556 9.37 IL1R1 IL18R1
12 cytokine-mediated signaling pathway GO:0019221 9.23 TNFRSF1A IL6 IL1RN IL1R1 IL10 CXCL8

Molecular functions related to Bone Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.26 IL6 IL10 CSF3 CSF1
2 interleukin-1 receptor activity GO:0004908 9.16 IL1R1 IL18R1
3 cytokine activity GO:0005125 9.1 IL6 IL1RN IL10 CXCL8 CSF3 CSF1

Sources for Bone Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....